Prelude Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview

Reuters

28 Oct 2024

* Prelude Therapeutics Inc is expected to show no change in quarterly revenue when it reports results on October 30 (estimated) for the period ending September 30 2024

*

* LSEG's mean analyst estimate for Prelude Therapeutics Inc is for a loss of 47 cents per share.

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and 2 "sell" or "strong sell."

* The mean earnings estimate of analysts had fallen by about 2.4% in the last three months.

* Wall Street's median 12-month price target for Prelude Therapeutics Inc is $5.00, above its last closing price of $1.52.

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jun. 30 2024 -0.43 -0.43 -0.46 Missed -7

Mar. 31 2024 -0.48 -0.48 -0.42 Beat 13.4

Jan. 1 0001 -0.49 -0.49 -0.46 Beat 6.1

Sep. 30 2023 -0.58 -0.58 -0.45 Beat 22.7

Jun. -0.64 -0.63 -0.54 Beat 14.7

30 2023

Mar. 31 2023 -0.69 -0.68 -0.58 Beat 15.3

Dec. 31 2022 -0.62 -0.63 -0.60 Beat 4.5

Jan. 1 0001 -0.63 -0.64 -0.63 Beat 0.9

This summary was machine generated October 28 at 13:04 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2478488071"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2478488071\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2478488071?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-28 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2478488071","market":"us","top_or_hot":-1,"title":"Prelude Therapeutics Inc    expected to post a loss of 47 cents a share - Earnings Preview","media":"Reuters","content":"<html><body><p>* <a href=\"https://laohu8.com/S/PRLD\">Prelude Therapeutics Inc</a>     is expected to show no change in quarterly revenue when it reports  results on October 30 (estimated) for the period ending September 30 2024</p><p>   * </p><p>   * LSEG's mean analyst estimate for Prelude <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc is for a loss of 47 cents per share. </p><p>   * The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy,\" no \"hold\" and 2 \"sell\" or \"strong sell.\"  </p><p>   * The mean earnings estimate of analysts had fallen by about 2.4% in the last three months. </p><p>   * Wall Street's median 12-month price target for Prelude Therapeutics Inc is $5.00, above its last closing price of $1.52. </p><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><p>QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI</p><p>ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %</p><p>              E®                               MISSED  </p><p>Jun. 30 2024  -0.43       -0.43      -0.46     Missed  -7</p><p>Mar. 31 2024  -0.48       -0.48      -0.42     Beat    13.4</p><p>Jan. 1 0001   -0.49       -0.49      -0.46     Beat    6.1</p><p>Sep. 30 2023  -0.58       -0.58      -0.45     Beat    22.7</p><p>Jun.        -0.64       -0.63      -0.54     Beat    14.7</p><p>30 2023                                                </p><p>Mar. 31 2023  -0.69       -0.68      -0.58     Beat    15.3</p><p>Dec. 31 2022  -0.62       -0.63      -0.60     Beat    4.5</p><p>Jan. 1 0001   -0.63       -0.64      -0.63     Beat    0.9</p><p>This summary was machine generated October 28 at 13:04 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Prelude Therapeutics Inc    expected to post a loss of 47 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrelude Therapeutics Inc    expected to post a loss of 47 cents a share - Earnings Preview\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-10-28 21:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>* <a href=\"https://laohu8.com/S/PRLD\">Prelude Therapeutics Inc</a>     is expected to show no change in quarterly revenue when it reports  results on October 30 (estimated) for the period ending September 30 2024</p><p>   * </p><p>   * LSEG's mean analyst estimate for Prelude <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc is for a loss of 47 cents per share. </p><p>   * The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy,\" no \"hold\" and 2 \"sell\" or \"strong sell.\"  </p><p>   * The mean earnings estimate of analysts had fallen by about 2.4% in the last three months. </p><p>   * Wall Street's median 12-month price target for Prelude Therapeutics Inc is $5.00, above its last closing price of $1.52. </p><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><p>QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI</p><p>ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %</p><p>              E®                               MISSED  </p><p>Jun. 30 2024  -0.43       -0.43      -0.46     Missed  -7</p><p>Mar. 31 2024  -0.48       -0.48      -0.42     Beat    13.4</p><p>Jan. 1 0001   -0.49       -0.49      -0.46     Beat    6.1</p><p>Sep. 30 2023  -0.58       -0.58      -0.45     Beat    22.7</p><p>Jun.        -0.64       -0.63      -0.54     Beat    14.7</p><p>30 2023                                                </p><p>Mar. 31 2023  -0.69       -0.68      -0.58     Beat    15.3</p><p>Dec. 31 2022  -0.62       -0.63      -0.60     Beat    4.5</p><p>Jan. 1 0001   -0.63       -0.64      -0.63     Beat    0.9</p><p>This summary was machine generated October 28 at 13:04 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRLD","symbol_name":"Prelude Therapeutics Inc","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2478488071","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478488071","pubTimestamp":1730120711,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"* Prelude Therapeutics Inc     is expected to show no change in quarterly revenue when it reports  results on October 30 (estimated) for the period ending September 30 2024   *    * LSEG's mean analys","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"PRLD":"Prelude Therapeutics Inc"},"translate_title":"Prelude Therapeutics Inc预计每股亏损47美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRLD":1},"content_text":"* Prelude Therapeutics Inc     is expected to show no change in quarterly revenue when it reports  results on October 30 (estimated) for the period ending September 30 2024   *    * LSEG's mean analyst estimate for Prelude Therapeutics Inc is for a loss of 47 cents per share.    * The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy,\" no \"hold\" and 2 \"sell\" or \"strong sell.\"     * The mean earnings estimate of analysts had fallen by about 2.4% in the last three months.    * Wall Street's median 12-month price target for Prelude Therapeutics Inc is $5.00, above its last closing price of $1.52. Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRIENDING        ARTESTIMAT  ESTIMATE             MET,    SE %              E®                               MISSED  Jun. 30 2024  -0.43       -0.43      -0.46     Missed  -7Mar. 31 2024  -0.48       -0.48      -0.42     Beat    13.4Jan. 1 0001   -0.49       -0.49      -0.46     Beat    6.1Sep. 30 2023  -0.58       -0.58      -0.45     Beat    22.7Jun.        -0.64       -0.63      -0.54     Beat    14.730 2023                                                Mar. 31 2023  -0.69       -0.68      -0.58     Beat    15.3Dec. 31 2022  -0.62       -0.63      -0.60     Beat    4.5Jan. 1 0001   -0.63       -0.64      -0.63     Beat    0.9This summary was machine generated October 28 at 13:04 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"preview","news_rank":0,"symbols":[],"gpt_button":1}}}